These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1140 related articles for article (PubMed ID: 28714406)

  • 41. Unmasking the Many Faces of Tumor-Associated Neutrophils and Macrophages: Considerations for Targeting Innate Immune Cells in Cancer.
    Keeley T; Costanzo-Garvey DL; Cook LM
    Trends Cancer; 2019 Dec; 5(12):789-798. PubMed ID: 31813456
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Harnessing tumor-associated macrophages as aids for cancer immunotherapy.
    Li X; Liu R; Su X; Pan Y; Han X; Shao C; Shi Y
    Mol Cancer; 2019 Dec; 18(1):177. PubMed ID: 31805946
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells.
    Rossi JF; Céballos P; Lu ZY
    Cancer Commun (Lond); 2019 Jun; 39(1):34. PubMed ID: 31200766
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interaction of tumor-associated macrophages and cancer chemotherapy.
    Larionova I; Cherdyntseva N; Liu T; Patysheva M; Rakina M; Kzhyshkowska J
    Oncoimmunology; 2019; 8(7):1596004. PubMed ID: 31143517
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials.
    Paliard X; Rixe O
    Target Oncol; 2019 Dec; 14(6):631-637. PubMed ID: 31595386
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Engineering chimeric antigen receptor-T cells for cancer treatment.
    Ye B; Stary CM; Li X; Gao Q; Kang C; Xiong X
    Mol Cancer; 2018 Feb; 17(1):32. PubMed ID: 29448937
    [TBL] [Abstract][Full Text] [Related]  

  • 48. One microenvironment does not fit all: heterogeneity beyond cancer cells.
    Kim IS; Zhang XH
    Cancer Metastasis Rev; 2016 Dec; 35(4):601-629. PubMed ID: 27858305
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting myeloid cells in the tumor sustaining microenvironment.
    Schupp J; Krebs FK; Zimmer N; Trzeciak E; Schuppan D; Tuettenberg A
    Cell Immunol; 2019 Sep; 343():103713. PubMed ID: 29129292
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
    Mooradian MJ; Sullivan RJ
    Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment.
    Yang L; Li A; Lei Q; Zhang Y
    J Hematol Oncol; 2019 Nov; 12(1):125. PubMed ID: 31775797
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target.
    Gambardella V; Castillo J; Tarazona N; Gimeno-Valiente F; Martínez-Ciarpaglini C; Cabeza-Segura M; Roselló S; Roda D; Huerta M; Cervantes A; Fleitas T
    Cancer Treat Rev; 2020 Jun; 86():102015. PubMed ID: 32248000
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting Tumor Microenvironment for Cancer Therapy.
    Roma-Rodrigues C; Mendes R; Baptista PV; Fernandes AR
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781344
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies.
    Xu MM; Pu Y; Zhang Y; Fu YX
    Trends Immunol; 2016 Feb; 37(2):141-153. PubMed ID: 26778079
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells.
    Ahmed N; Escalona R; Leung D; Chan E; Kannourakis G
    Semin Cancer Biol; 2018 Dec; 53():265-281. PubMed ID: 30317036
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity.
    Janji B; Berchem G; Chouaib S
    Front Immunol; 2018; 9():887. PubMed ID: 29922284
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The application of the fibroblast activation protein α-targeted immunotherapy strategy.
    Jiang GM; Xu W; Du J; Zhang KS; Zhang QG; Wang XW; Liu ZG; Liu SQ; Xie WY; Liu HF; Liu JS; Wu BP
    Oncotarget; 2016 May; 7(22):33472-82. PubMed ID: 26985769
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting tumor-associated macrophages to combat pancreatic cancer.
    Cui R; Yue W; Lattime EC; Stein MN; Xu Q; Tan XL
    Oncotarget; 2016 Aug; 7(31):50735-50754. PubMed ID: 27191744
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy.
    Abou Khouzam R; Goutham HV; Zaarour RF; Chamseddine AN; Francis A; Buart S; Terry S; Chouaib S
    Semin Cancer Biol; 2020 Oct; 65():140-154. PubMed ID: 31927131
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potential applications of macrophages in cancer immunotherapy.
    Sadri M; Heidari S; Faridzadeh A; Roozbehani M; Toosi S; Mahmoudian RA; Hoseinzadeh A; Salmani Fard MT; Arab FL; Fard SR; Faraji F
    Biomed Pharmacother; 2024 Sep; 178():117161. PubMed ID: 39047419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.